Enrollment completed for DengiAll Phase III with 10,335 participants. Two-year follow-up planned to assess efficacy and immunogenicity; expected to launch in India by 2027 as the first indigenous single-shot dengue vaccine.
AI Assistant
Panacea Biotec Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.